Scott Fettner

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition

Ashok Rakhit, Michael Pantze, Scott Fettner et al. · European Journal of Clinical Pharmacology · 2007 · 120 citations

Pharmacokinetic Modeling, Cyp3a4 Inhibition, Erlotinib Pharmacokinetics +8

Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma

Robert J. Motzer, Ashok Rakhit, Michelle S. Ginsberg et al. · Journal of Clinical Oncology · 2001 · 101 citations

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA

Hisham Abdallah, Joy Hsu, Peng Lü et al. · The Journal of Clinical Pharmacology · 2016 · 94 citations · Full text

Immunology, Pharmacotherapy, Immunotherapy +16

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

Jie Ling, Scott Fettner, Bert L. Lum et al. · Anti-Cancer Drugs · 2008 · 86 citations

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study

Chris Twelves, José Trigo, Robert H. Jones et al. · European Journal of Cancer · 2008 · 52 citations

Dose-escalation Study, Metastatic Breast Cancer, Oncology +7